Antibiotic resistance is a significant public health issue, causing illnesses that were once
easily treatable with antibiotics to develop into dangerous infections, leading to substantial …

Recent advances in the understanding of immune function and the interactions with tumour
cells have led to the development of various cancer immunotherapies and strategies for …

Abstract Programmed death-1 (PD-1) and its ligand are part of the immune checkpoint
pathway that down-regulates effector T cells in immune response, thereby causing immune …

Monoclonal antibody technology plays a vital role in biomedical and immunotherapy, which
greatly promotes the study of the structure and function of genes and proteins. To date …

Ovarian cancer is a leading cause of death from gynecological malignancies. Although the
prognosis is quite favorable if detected at an early stage, the vast majority of cases are …

Abstract The approvals of Provenge (Sipuleucel-T), Ipilimumab (Yervoy/anti-CTLA-4) and
blockers of the PD-1-PD-L1/PD-L2 pathway, such as nivolumab (Opdivo), pembrolizumab …

Aim In advanced, platinum resistant or refractory ovarian cancer (OC), the therapeutic
efficacy of carboplatin is controversial. Although anti‐programmed death‐1/programmed …

In cancer patients, the immune system is often altered with an excess of inhibitory factors,
such as immunosuppressive cytokines, produced by regulatory T cells (Treg) or myeloid …

Pyroptosis, a form of inflammatory programmed cell death, is accompanied by inflammation
and participate in the body's immune response. The expression of pyroptosis-related genes …

Ovarian cancer (OC) is the sixth most common cancer worldwide among women, and, in
developed countries, it is the leading cause of mortality among gynecological malignancies …